Horizon Discovery acquires Sage Labs for $48 million

UK-based Horizon Discovery Group (LSE: HZD) has agreed to acquire Sage Labs of the USA for up to $16 million in cash and up to $32 million through the issue of new ordinary shares.

The acquisition of Sage, which specializes in the generation of advanced in vivo transgenic disease models for use in preclinical research, builds on the acquisition of CombinatoRx in July and makes Horizon the world’s leading gene-editing company and the go-to company for the provision of integrated product, service and research solutions at all stages of translational genomics and personalized medicine research from sequence to treatment.

The acquisition, which is in line with the stated strategy to build a fully-integrated life science business, provides Horizon with an expanded range of genetically engineered preclinical models, important tools for the discovery and development of medicines targeted to the unique genetic drivers of diseases like cancer.

Includes direct US and EU sales force